250 related articles for article (PubMed ID: 32488496)
1. Prostaglandin E2 receptor 3 (EP3) signaling promotes migration of cervical cancer via urokinase-type plasminogen activator receptor (uPAR).
Ye Y; Peng L; Vattai A; Deuster E; Kuhn C; Dannecker C; Mahner S; Jeschke U; von Schönfeldt V; Heidegger HH
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2189-2203. PubMed ID: 32488496
[TBL] [Abstract][Full Text] [Related]
2. Prostaglandin E
Lian S; Xia Y; Ung TT; Khoi PN; Yoon HJ; Lee SG; Kim KK; Jung YD
Mol Carcinog; 2017 Feb; 56(2):664-680. PubMed ID: 27377703
[TBL] [Abstract][Full Text] [Related]
3. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
Xue A; Xue M; Jackson C; Smith RC
Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
5. Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion.
Magnussen SN; Hadler-Olsen E; Costea DE; Berg E; Jacobsen CC; Mortensen B; Salo T; Martinez-Zubiaurre I; Winberg JO; Uhlin-Hansen L; Svineng G
BMC Cancer; 2017 May; 17(1):350. PubMed ID: 28526008
[TBL] [Abstract][Full Text] [Related]
6. A retrospective study of urokinase-type plasminogen activator receptor (uPAR) as a prognostic factor in cancer of the uterine cervix.
Sasaki T; Nishi H; Nagata C; Nagai T; Nagao T; Terauchi F; Isaka K
Int J Clin Oncol; 2014 Dec; 19(6):1059-64. PubMed ID: 24474395
[TBL] [Abstract][Full Text] [Related]
7. The Prostaglandin EP3 Receptor Is an Independent Negative Prognostic Factor for Cervical Cancer Patients.
Heidegger H; Dietlmeier S; Ye Y; Kuhn C; Vattai A; Aberl C; Jeschke U; Mahner S; Kost B
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28753926
[TBL] [Abstract][Full Text] [Related]
8. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
9. Prostaglandin E2 increases migration and proliferation of human glioblastoma cells by activating transient receptor potential melastatin 7 channels.
Tian Y; Yang T; Yu S; Liu C; He M; Hu C
J Cell Mol Med; 2018 Dec; 22(12):6327-6337. PubMed ID: 30338939
[TBL] [Abstract][Full Text] [Related]
10. Prostaglandin E2 promotes human cholangiocarcinoma cell proliferation, migration and invasion through the upregulation of β-catenin expression via EP3-4 receptor.
Du M; Shi F; Zhang H; Xia S; Zhang M; Ma J; Bai X; Zhang L; Wang Y; Cheng S; Yang Q; Leng J
Oncol Rep; 2015 Aug; 34(2):715-26. PubMed ID: 26058972
[TBL] [Abstract][Full Text] [Related]
11. The prostaglandin receptor EP2 determines prognosis in EP3-negative and galectin-3-high cervical cancer cases.
Dietlmeier S; Ye Y; Kuhn C; Vattai A; Vilsmaier T; Schröder L; Kost BP; Gallwas J; Jeschke U; Mahner S; Heidegger HH
Sci Rep; 2020 Jan; 10(1):1154. PubMed ID: 31980713
[TBL] [Abstract][Full Text] [Related]
12. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
Allan EH; Martin TJ
J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
[TBL] [Abstract][Full Text] [Related]
13. Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness.
Bryan L; Paugh BS; Kapitonov D; Wilczynska KM; Alvarez SM; Singh SK; Milstien S; Spiegel S; Kordula T
Mol Cancer Res; 2008 Sep; 6(9):1469-77. PubMed ID: 18819934
[TBL] [Abstract][Full Text] [Related]
14. Quercetin Has Antimetastatic Effects on Gastric Cancer Cells via the Interruption of uPA/uPAR Function by Modulating NF-κb, PKC-δ, ERK1/2, and AMPKα.
Li H; Chen C
Integr Cancer Ther; 2018 Jun; 17(2):511-523. PubMed ID: 28627240
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin E2 Reduces Cardiac Contractility via EP3 Receptor.
Gu X; Xu J; Zhu L; Bryson T; Yang XP; Peterson E; Harding P
Circ Heart Fail; 2016 Aug; 9(8):. PubMed ID: 27502370
[TBL] [Abstract][Full Text] [Related]
16. The effects of cyclooxygenase2-prostaglandinE2 pathway on Helicobacter pylori-induced urokinase-type plasminogen activator system in the gastric cancer cells.
Iwamoto J; Mizokami Y; Takahashi K; Matsuoka T; Matsuzaki Y
Helicobacter; 2008 Jun; 13(3):174-82. PubMed ID: 18466392
[TBL] [Abstract][Full Text] [Related]
17. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
[TBL] [Abstract][Full Text] [Related]
18. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Gnessi L; Catania A; Pellizzo MR; Nardi F; Mian C; De Antoni E; D'Armiento M; Frati L
J Clin Endocrinol Metab; 2011 Feb; 96(2):504-8. PubMed ID: 21106716
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
20. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
